Anti-LRG1 / Leucine-rich alpha-2-glycoprotein 1

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. LRG1 antibody detects Leucine-rich alpha-2-glycoprotein 1, a secreted glycoprotein that regulates angiogenesis, inflammation, and tissue remodeling. The UniProt recommended name is Leucine-rich alpha-2-glycoprotein 1 (LRG1). This plasma protein belongs to the leucine-rich repeat (LRR) family and interacts with transforming growth factor-beta (TGF-beta) signaling pathways to influence vascular and immune responses.Functionally, LRG1 antibody identifies a 312-amino-acid glycoprotein composed of eight leucine-rich repeats forming a curved solenoid structure. LRG1 modulates endothelial cell behavior by binding endoglin and shifting TGF-beta signaling from the ALK5/SMAD2/3 axis to the ALK1/SMAD1/5/8 pathway, promoting angiogenesis. It also serves as an acute-phase reactant, increasing during infection, inflammation, and tissue injury.The LRG1 gene is located on chromosome 19p13.3 and is highly expressed in liver, endothelial cells, and neutrophils. LRG1 is secreted into plasma, cerebrospinal fluid, and extracellular matrix, where it influences cell adhesion, migration, and vascular remodeling. Elevated serum LRG1 is a biomarker of cardiovascular and inflammatory diseases.Pathologically, dysregulation of LRG1 contributes to diabetic retinopathy, fibrosis, tumor angiogenesis, and inflammatory disorders. Overexpression of LRG1 promotes abnormal vessel formation and tissue remodeling, while inhibition can suppress pathological angiogenesis. Research using LRG1 antibody supports studies in vascular biology, immunology, and biomarker discovery.LRG1 antibody is validated for ELISA, western blotting, and immunohistochemistry to detect secreted and tissue-associated glycoproteins. NSJ Bioreagents provides LRG1 antibody reagents optimized for studies of angiogenesis, extracellular signaling, and disease pathophysiology.Structurally, Leucine-rich alpha-2-glycoprotein 1 adopts a horseshoe-shaped LRR domain that mediates protein-protein interactions with growth factors and receptors. This antibody enables investigation of LRG1's role in vascular signaling and disease progression.